BridgeMD
New treatment option for Non-Traumatic Subarachnoid Hemorrhage
Official title Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
ClinicalTrials.gov ID: NCT06569212
What this study is testing
What is Metoprolol?
Metoprolol is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for non-traumatic subarachnoid hemorrhage.
Also referred to as Metoprolol succinate.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- \>18 years of age
- Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage
You likely can't join if
- Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage.
- Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage
- Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating)
- Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including:
- Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications
- Heart rate \< 50 bpm associated with hypotension
See the full eligibility criteria
- \>18 years of age
- Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage
- Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage.
- Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage
- Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating)
- Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including:
- Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications
- Heart rate \< 50 bpm associated with hypotension
- Patients requiring vasopressor agents due to hypotension (SBP \<80 mmHg)
- Other vital sign exclusion at the discretion of the treatment team
- Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV)
- Patient or legally authorized representative unwilling to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Portland, Maine, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Portland, Maine, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.